Breaking News Instant updates and real-time market news.

CFRX

ContraFect

$0.85

0.0012 (0.14%)

07:14
01/10/20
01/10
07:14
01/10/20
07:14

ContraFect announces first patient dosed in Phase 3 DISRUPT study of Exebacase

ContraFect Corporation announced the first patient has been dosed in the Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the U.S. to assess the efficacy and safety of exebacase in approximately 350 patients with complicated Staph aureus bacteremia, including right-sided endocarditis. Patients entering the Phase 3 study will be randomized 2:1 to either exebacase or placebo, with all patients receiving standard-of-care antibiotics. The primary efficacy endpoint will be clinical response at Day 14 in patients with MRSA bacteremia, including right-sided endocarditis. Secondary endpoints will include clinical response at Day 14 in the All Staph aureus patients (MRSA and methicillin-sensitive Staph aureus, 30-day all-cause mortality in MRSA patients, and clinical response at later timepoints. The company plans to conduct an interim futility analysis following the enrollment of approximately 60% of the study population.

  • 31

    Jan

CFRX ContraFect
$0.85

0.0012 (0.14%)

06/11/19
MAXM
06/11/19
INITIATION
Target $2
MAXM
Buy
ContraFect initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated ContraFect with a Buy rating and a price target of $2, citing the company's lysins development efforts to become "a new class of non-antibiotic anti-infective that can mitigate drug resistance." The analyst notes that the valuation on the stock has been suppressed by the phase 2 trial study miss on the primary endpoint of responder rate, though that may have been due to "an imbalance in the number of left-sided endocarditis patients" in the study. McCarthy contends that ContraFect valuation may remain "in the penalty box", but believes that its Exebacase should have a path forward to a phase 3 study, with lysins possibly emerging as a "new class of non-antibiotic anti-infective."
10/02/19
PIPR
10/02/19
NO CHANGE
Target $3.5
PIPR
Overweight
Piper says design differentiates ContraFect trial from other antibiotic studies
The FDA has agreed to a single Phase 3 trial of exebacase to treat S. aureus bacteremia, noted Piper Jaffray analyst Edward Tenthoff, who said the superiority design differentiates DISRUPT from other antibiotic studies. The analyst, who also noted that the FDA agreed to accept a license application filing on positive superiority data, keeps an Overweight rating and $3.50 price target on ContraFect shares following the company's announcement of the FDA agreement.

TODAY'S FREE FLY STORIES

ODP

Office Depot

$2.59

(0.00%)

09:41
01/21/20
01/21
09:41
01/21/20
09:41
Hot Stocks
Office Depot, Shipt announce same-day delivery partnership »

Shipt announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAK

Northern Dynasty

$0.41

(0.00%)

, HSY

Hershey

$150.93

(0.00%)

09:40
01/21/20
01/21
09:40
01/21/20
09:40
Options
Unusually active option classes on open January 21st »

Unusual total active…

NAK

Northern Dynasty

$0.41

(0.00%)

HSY

Hershey

$150.93

(0.00%)

BK

BNY Mellon

$46.18

(0.00%)

MDLZ

Mondelez

$55.15

(0.00%)

PAAS

Pan American Silver

$21.33

(0.00%)

FXI

iShares China Large-Cap ETF

$45.09

(0.00%)

HAL

Halliburton

$23.96

(0.00%)

UAL

United Airlines

$89.68

(0.00%)

DAL

Delta Air Lines

$62.01

(0.00%)

WYNN

Wynn Resorts

$151.51

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 22

    Jan

  • 29

    Jan

  • 30

    Jan

  • 06

    Feb

  • 17

    Feb

  • 20

    Feb

  • 23

    Mar

STT

State Street

$82.51

1.505 (1.86%)

09:39
01/21/20
01/21
09:39
01/21/20
09:39
Recommendations
State Street analyst commentary  »

State Street price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 26

    Feb

LTC

LTC Properties

$46.75

-0.085 (-0.18%)

09:38
01/21/20
01/21
09:38
01/21/20
09:38
Hot Stocks
LTC Properties announces three acquisitions for $33M »

LTC Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTXP

Foothills Exploration

$0.00

(0.00%)

09:35
01/21/20
01/21
09:35
01/21/20
09:35
Hot Stocks
Foothills Exploration says has no plans to do a reverse-split »

Foothills Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDOC

Teladoc

$95.60

-1.22 (-1.26%)

09:35
01/21/20
01/21
09:35
01/21/20
09:35
Recommendations
Teladoc analyst commentary  »

Teladoc price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCOM

Trip.com Group

$38.95

0.5 (1.30%)

09:34
01/21/20
01/21
09:34
01/21/20
09:34
Downgrade
Trip.com Group rating change  »

Trip.com Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$3.32

0.14 (4.40%)

09:32
01/21/20
01/21
09:32
01/21/20
09:32
Hot Stocks
Neovasc expects to initial clinical feasibility study for Tiara in late 2020 »

The TF/TS development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$3.32

0.14 (4.40%)

09:31
01/21/20
01/21
09:31
01/21/20
09:31
Hot Stocks
Neovasc confirms pre-funded warrants from $10M financing have been exercised »

The Company confirms that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:31
01/21/20
01/21
09:31
01/21/20
09:31
Conference/Events
World Economic Forum hosts annual meeting »

Davos Annual Meeting 2020…

BLNK

Blink Charging

$2.06

-0.085 (-3.97%)

09:30
01/21/20
01/21
09:30
01/21/20
09:30
Hot Stocks
Interenergy purchases $1.2M of Blink Charging EV charging equipment »

Blink Charging announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVAX

Novavax

$5.75

0.965 (20.19%)

, INO

Inovio

$3.30

-0.105 (-3.09%)

09:29
01/21/20
01/21
09:29
01/21/20
09:29
Hot Stocks
Novavax soars 64% as unknown virus spreads through China »

Shares of antibiotics…

NVAX

Novavax

$5.75

0.965 (20.19%)

INO

Inovio

$3.30

-0.105 (-3.09%)

BCRX

BioCryst

$2.79

-0.03 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNT

Kornit Digital

$40.79

0.2 (0.49%)

09:28
01/21/20
01/21
09:28
01/21/20
09:28
Recommendations
Kornit Digital analyst commentary  »

Kornit Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTCC

Key Tronic

$6.77

-0.04 (-0.59%)

09:27
01/21/20
01/21
09:27
01/21/20
09:27
Earnings
KeyTronic sees Q3 EPS 13c-17c »

Sees revenue $117M-$121M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTCC

Key Tronic

$6.77

-0.04 (-0.59%)

09:26
01/21/20
01/21
09:26
01/21/20
09:26
Hot Stocks
Keytronic sees Q2 EPS of approx. 8c, below previous guidance »

Sees Q2 revenue $117M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$23.96

0.15 (0.63%)

09:26
01/21/20
01/21
09:26
01/21/20
09:26
Hot Stocks
Halliburton sees Q1 completion & production segment sequential revenue up 2%-4% »

Sees drilling &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 23

    Mar

AMGN

Amgen

$241.53

1.01 (0.42%)

09:26
01/21/20
01/21
09:26
01/21/20
09:26
Upgrade
Amgen rating change  »

Amgen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

INVE

Identiv

$6.31

-0.19 (-2.92%)

09:25
01/21/20
01/21
09:25
01/21/20
09:25
Hot Stocks
Identiv, SiteWatch partner for cloud-based emergency electronic mustering »

Identiv announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
01/21/20
01/21
09:25
01/21/20
09:25
General news
Treasury Action: yields are richening as volume picks up »

Treasury Action: yields…

MYO

Myomo

$0.32

0.0062 (1.98%)

09:25
01/21/20
01/21
09:25
01/21/20
09:25
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

09:25
01/21/20
01/21
09:25
01/21/20
09:25
Conference/Events
UBS leisure analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

09:25
01/21/20
01/21
09:25
01/21/20
09:25
Conference/Events
Telsey Advisory analysts to hold an analyst/industry conference call »

Analysts, along with Jack…

TDY

Teledyne

$376.53

-1.17 (-0.31%)

09:24
01/21/20
01/21
09:24
01/21/20
09:24
Recommendations
Teledyne analyst commentary  »

Teledyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CDW

CDW

$136.96

-7.22 (-5.01%)

, KSS

Kohl's

$46.98

-0.03 (-0.06%)

09:24
01/21/20
01/21
09:24
01/21/20
09:24
Hot Stocks
CDW names Sona Chawla chief growth, innovation officer »

The company announced the…

CDW

CDW

$136.96

-7.22 (-5.01%)

KSS

Kohl's

$46.98

-0.03 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HAL

Halliburton

$23.96

0.15 (0.63%)

09:23
01/21/20
01/21
09:23
01/21/20
09:23
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 23

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.